# NCT03802695 (NCT03802695)

> A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03802695
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Orca Biosystems, Inc.
- Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Mixed Phenotype Acute Leukemia; Acute Lymphoblastic Leukemia
- Interventions: OrcaGraft (Orca-Q)
- Enrollment: 300
- Primary outcome: Dose Limiting Toxicities through Day +28 (dose escalation)
- Primary outcome: Primary Graft failure through Day +28 (dose expansion)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03802695